MYR-101

N/A

Report date: 2025/07/18 17:54:08

Base Information

Drug NameMYR-101
Drug Alias NamerAAV-Olig001-ASPAMyr-101AVASPA
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionASPA gene stimulants
TargetsAspartoacylase
Therapy Area/IndicationsCanavan Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesMyrtelle Inc
Inactive CompaniesN/A
Active IndicationsCanavan Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A